Medical liability reform is gaining more attention as critical for ensuring access to care and spurring development of new medical treatments.
WASHINGTON, D.C.-Medical liability reform is gaining more attention as critical for ensuring access to care and spurring development of new medical treatments.
A liability protection provision, for example, was included in legislation that Congress approved in December to launch the administration's Pandemic Influenza plan. Language providing liability protection for manufacturers of pandemic countermeasures was added to the $453 billion 2006 defense appropriations bill, which provides $3.8 billion to support national emergency preparedness and the development of new vaccines and drugs.
BROAD MEASURE
Separately, an analysis of emergency medical care across the country down-rates many states due to their poor "medical liability environment," according to the American College of Emergency Physicians (ACEP).
In developing a report card on the nation's emergency medicine capabilities, ACEP gave points to states that have adopted caps on non-economic damage awards.
The report card also rates states on three other measures: access to emergency care; quality and patient safety; and public health and injury prevention.
These categories evaluate a state's percentage of uninsured; availability of hospital beds and emergency specialists; access to ambulances and 911 services; local injury prevention programs; and immunization rates. Only a handful of states received "B" ratings, while most scored only "Cs" and "Ds."
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
More Results for Nerandomilast Reported by BI, This Time for Progressive Pulmonary Fibrosis
February 15th 2025Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen